Nesler_Katherine

Katherine Nesler, PhD

Senior Associate

Katherine Nesler focuses her practice on patent matters in the life sciences and biotechnology areas. She represents clients in patent litigation cases in district court cases and in inter partes review proceedings before the US Patent and Trademark Office. Dr. Nesler also provides clients with a broad range of intellectual property services, including patent procurement, strategic patent counseling, freedom-to-operate and due diligence.

Dr. Nesler has experience assisting clients ranging from startups to large companies, along with research and academic institutions in a wide variety of technologies including genome editing (e.g., CRISPR/Cas systems), gene therapies, chimeric antigen receptor (CAR) therapies, vaccines, biological and small molecule therapeutics, antibodies and antibody-drug conjugates, sequencing technologies, in silico modeling of biological processes, and genetic biologic diagnostic methods.

Prior to joining WilmerHale, Dr. Nesler was an associate in the Los Angeles office of another large law firm.

Credentials

  • Education

    • JD, Washington University School of Law, 2017

      cum laude

      Editor-in-Chief, Journal of Law and Policy

    • PhD, Biology, University of Denver, 2014

    • BS, Molecular Biology, Minors in Chemistry and Medical Physics, University of Denver, 2009

  • Admissions

    • California

    • Colorado

    • US District Court for the Central District of California

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.